For example, the scFv Brolucizumab, directed against VEGF, is approved for the treatment of macular degeneration, and DLX105, directed against tumor necrosis factor alpha, demonstrated a positive outcome on psoriasis biomarkers in a clinical study [48,49]. The gene discussed is VEGFA; the disease is psoriasis.